Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 223, Issue -, Pages 390-397Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2016.08.204
Keywords
Procalcitonin; Dyspnea; Biomarker
Categories
Funding
- Biomarker company
- BRAHMS/Thermofisher
- BioMerieux
- Roche Diagnostics
Ask authors/readers for more resources
Due to its high accuracy for the diagnosis of bacterial infections, the inflammatory biomarker procalcitonin (PCT) is increasingly being used in patients with suspected infection. In patients with infections of the respiratory tract, it allows rapid rule out of bacterial etiology and facilitates decisions pertaining to antibiotic management. A growing body of evidence also supports PCT testing in patients with cardiovascular disorders including, but not limited to, those with shortness of breath, possible heart failure, suspected endocarditis, and acute coronary syndromes. In these clinical situations, PCT may provide diagnostic information on the likelihood of an infectious cause in cardiovascular patients presenting with acute symptoms such as dyspnea. It may also have a prognostic value that correlates with clinical outcome and can potentially guide drug therapy. This narrative review summarizes current concepts and evidence from the published literature on the strengths and limitations of PCT as a biomarker, with a focus on patients with a variety of cardiovascular disorders. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available